BBR Partners LLC Acquires 200,000 Shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)

BBR Partners LLC raised its holdings in shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) by 74.1% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 470,000 shares of the biopharmaceutical company’s stock after purchasing an additional 200,000 shares during the period. BBR Partners LLC owned approximately 0.19% of Lexicon Pharmaceuticals worth $738,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of the business. CVI Holdings LLC purchased a new stake in shares of Lexicon Pharmaceuticals during the second quarter valued at $34,000. Principal Financial Group Inc. boosted its holdings in shares of Lexicon Pharmaceuticals by 116.1% during the 2nd quarter. Principal Financial Group Inc. now owns 22,759 shares of the biopharmaceutical company’s stock valued at $38,000 after acquiring an additional 12,225 shares during the last quarter. Great Point Partners LLC purchased a new stake in shares of Lexicon Pharmaceuticals during the 2nd quarter valued at about $50,000. BNP Paribas Financial Markets grew its stake in shares of Lexicon Pharmaceuticals by 71.2% in the third quarter. BNP Paribas Financial Markets now owns 31,853 shares of the biopharmaceutical company’s stock worth $50,000 after acquiring an additional 13,246 shares during the period. Finally, SG Americas Securities LLC raised its holdings in shares of Lexicon Pharmaceuticals by 107.6% during the third quarter. SG Americas Securities LLC now owns 46,090 shares of the biopharmaceutical company’s stock valued at $72,000 after purchasing an additional 23,893 shares during the last quarter. Institutional investors own 74.70% of the company’s stock.

Lexicon Pharmaceuticals Stock Down 1.9 %

Shares of LXRX stock opened at $0.80 on Thursday. The company has a current ratio of 7.45, a quick ratio of 7.43 and a debt-to-equity ratio of 0.56. Lexicon Pharmaceuticals, Inc. has a 12 month low of $0.73 and a 12 month high of $3.73. The stock has a market cap of $198.20 million, a P/E ratio of -1.07 and a beta of 1.24. The company has a 50 day simple moving average of $1.48 and a two-hundred day simple moving average of $1.68.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last announced its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.01). Lexicon Pharmaceuticals had a negative return on equity of 107.38% and a negative net margin of 4,109.41%. The company had revenue of $1.75 million during the quarter, compared to the consensus estimate of $3.14 million. During the same period in the prior year, the business posted ($0.21) earnings per share. On average, research analysts expect that Lexicon Pharmaceuticals, Inc. will post -0.69 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the stock. HC Wainwright restated a “buy” rating and issued a $6.00 target price on shares of Lexicon Pharmaceuticals in a report on Wednesday, November 13th. Leerink Partners set a $6.00 price objective on Lexicon Pharmaceuticals and gave the stock an “outperform” rating in a report on Friday, October 18th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Lexicon Pharmaceuticals in a research report on Friday, November 22nd. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $6.00.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.